Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03567681
Recruitment Status : Unknown
Verified June 2018 by Collaborative Care Initiative, LLC.
Recruitment status was:  Enrolling by invitation
First Posted : June 26, 2018
Last Update Posted : June 26, 2018
Sponsor:
Collaborator:
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen Hospital
Information provided by (Responsible Party):
Collaborative Care Initiative, LLC

Brief Summary:
Consenting subjects with Bipolar depression will remain under the care of their local (psychiatric) care provider and be randomized to a six week course of one of two forms of oxcarbazepine (extended release or immediate release. Study outcomes will be assessed based on outcome measures administered to the subject at home by a computer simulated rater. Local care providers will receive "pre-assessment" reports ahead of each clinical visit, rate the Clinical Global Impression for Severity, and evaluate adverse effects. The primary outcome variable is "treatment effectiveness" operationally defined as the response rate X the completion rate.

Condition or disease Intervention/treatment Phase
Bipolar Depression Treatment Effectiveness Measure-based Guidance Drug: Extended release oxcarbazepine vs Immediate release oxcarbazepine Phase 4

Detailed Description:

This study will use the CCI Engaged Practice platform (EngagedPractice.Com) and will be conducted by a central "meta-site" reviewing eligibility, obtaining consent, randomizing subjects to treatment groups, training local care providers (LCP) to function as sub- investigators and monitoring outcomes.

Subjects will be randomized to six weeks of treatment with extended release oxcarbazepine or immediate release oxcarbazepine,while remaining under the care of their existing LCP.

LCP's will receive sub-investigator training for Good Clinical Practice, Human subjects protection, and all protocol specified assessments and procedures.

A computer simulated rater will collect outcomes (including MADRS, YMRS, PHQ-9, and adverse effects) ahead of each routine clinical visit and provide Measure-based Guidance o the LCP in the form of pre-assessment reports. The primary outcome variable is "treatment effectiveness" operationally defined as the response rate X the completion rate.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open randomization to parallel treatment groups
Masking: None (Open Label)
Masking Description: Outcome will be assessed by computer
Primary Purpose: Treatment
Official Title: An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression
Estimated Study Start Date : June 13, 2018
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : September 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Extended release oxcarbazepine
Six week of open treatment with extended release oxcarbazepine (Oxtellar XR)
Drug: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Extended release oxcarbazepine vs Immediate release oxcarbazepine
Other Name: Oxtellar vs Trileptal

Experimental: Immediate release oxcarbazepine
Six week of open treatment with Immediate release oxcarbazepine ( Trileptal)
Drug: Extended release oxcarbazepine vs Immediate release oxcarbazepine
Extended release oxcarbazepine vs Immediate release oxcarbazepine
Other Name: Oxtellar vs Trileptal




Primary Outcome Measures :
  1. Treatment Effectiveness [ Time Frame: 6 weeks ]
    Treatment Effectiveness is defined as Response Rate (Change from Baseline MADRS > or = 50%) X Completion Rate (completes week 6 of protocol while remaining on assigned treatment).


Secondary Outcome Measures :
  1. Tolerability [ Time Frame: 6 weeks ]
    Tolerability is defined as the rate of completion without severe adverse effects reported by subject or clinician. The subject will complete an adverse effects self-report module as part of their "Online Pre-assessment" 1-3 days prior to each clinical visit. The clinician will review the pre-assessment and complete their own adverse effect report at each visit. Items rated as severe by either the subject or the clinician will will be counted as severe. Subjects who remain on study medication for 6 weeks without severe adverse effects will be scored as tolerating treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: The protocol is designed to collect evidence from subjects during the course of routine clinical care. Enrollment is limited to consenting subjects with a current local care provider who agrees that oxcarbazepine is a reasonable next step in managing their bipolar depression

  1. Adults male or female, 18-65 years of age, inclusive, at the time of informed consent.
  2. Able to access the internet for computer administered ratings.
  3. Lifetime mood disorder Diagnosis of Bipolar disorder I or II and a current episode meeting criteria for MDE with or without mixed features according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) at screen and baseline and confirmed by the Collaborative Care Initiative (CCI) review of pre-assessment including bipolarity index score ≥ 50,
  4. Severity of current MDE at least moderate depression as defined by Montgomery Asberg Depression Rating Scale (MADRS) ≥20 and least three symptoms of DSM 5 MDE criteria meet threshold for counting toward a current MDE diagnosis (item scores ≥4) at screen and baseline.
  5. Duration of current MDE at baseline is at least 4 weeks in and no longer than 2 years
  6. Cycle frequency does not exceed 8 mood episodes in the past 365 days.
  7. Current treatment regimen stable for at least 4 weeks and must include at least one of three acceptable medication types, but no more than 1 from each class: lithium, one dopamine-blocking agent, one standard antidepressant medication.
  8. The LCP agrees that treatment with oxcarbazepine is appropriate, completes study training, and agrees to complete all protocol management and record keeping requirements.
  9. Any urine toxicology screens for drugs of abuse (cocaine, amphetamines, barbiturates, opiates, benzodiazepines, and cannabinoids) and alcohol in the 6 months prior to the baseline visit have been negative. Note any positive test result(s) for benzodiazepines accompanied by confirmation of a prescription for a valid medical reason will be allowed.
  10. Negative urine pregnancy test at screen or baseline visit.
  11. Sexually active women, unless surgically sterile (at least six months prior to study drug administration) or at least one year post-menopausal, must have used an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of condom with spermicide by sexual partner or sterile [at least six months prior to study drug administration] sexual partner) for at least four weeks prior to study drug administration, and must have agreed to continue using such precautions through the End of Study visit. Cessation of birth control after this point was to be discussed with a responsible physician.
  12. At least one set of clinical labs including serum sodium, creatinine and TSH have been obtained and within normal limits within the 3 months prior to the baseline visit.

Exclusion Criteria:

  1. Inability to provide informed consent in English
  2. Current or lifetime diagnosis of epilepsy
  3. Pregnancy, breastfeeding or refusal to use birth control
  4. Another current Axis I diagnosis that is the primary focus of current treatment
  5. Substance or alcohol abuse/dependence at least 6 months prior enrollment
  6. Clinically significant abnormal results on clinical laboratories (including serum Creatinine, Sodium, and TSH) at baseline visit or within the prior 3 months.
  7. Has started treatment with an FDA approved agent for Bipolar depression within the past 4 weeks
  8. Has received treatment with a long-acting injectable antipsychotic or electroconvulsive therapy during the 2 months prior screening
  9. If psychotropic medication outside of study limits is required (Note: Subjects may receive any concomitant medications prescribed by their local care providers with the following specific exceptions: Anti-anxiety medications (anxiolytics) exceeding equivalent of lorazepam 2 mg/d.
  10. Any long-acting injectable antipsychotic, More than one dopamine blocking agent, More than one standard antidepressant agent, FDA approved treatments for Bipolar depression (quetiapine, lurasidone, the combination of olanzapine and fluoxetine), or Electroconvulsive therapy.)
  11. Last dose of another anticonvulsant agent taken in the current week or within 5 half-lives of discontinuation (whichever is longer) prior to enrollment in the study
  12. Current treatment requires ongoing anti-anxiety medications (Anxiolytics) exceeding equivalent of lorazepam 2 mg/d.
  13. Use of oxcarbazepine (OXC) for treatment of current episode
  14. Previous known hypersensitivity to OXC or other related drugs, such as carbamazepine.
  15. History or presence of clinically significant, chronic medical condition, (e.g., hyponatremia, any neurological, gastrointestinal, endocrine, cardiovascular, pulmonary, hematological, immunologic, renal, hepatic or metabolic disease) that in the opinion of the clinician or investigator may affect the safety of the subject and the participation to the trial.
  16. Active Suicidality (MADRS item 10 >4) Active suicidal plan/intent or active suicidal thoughts in the past 6 months. Any suicide attempt within two years of the screening assessment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03567681


Locations
Layout table for location information
United States, Massachusetts
Dauten Family Center for Bipolar Treatment Innovation
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Collaborative Care Initiative, LLC
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen Hospital
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Collaborative Care Initiative, LLC
ClinicalTrials.gov Identifier: NCT03567681    
Other Study ID Numbers: CCI-BD-001
First Posted: June 26, 2018    Key Record Dates
Last Update Posted: June 26, 2018
Last Verified: June 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Depressive Disorder
Bipolar Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Bipolar and Related Disorders
Oxcarbazepine
Anticonvulsants
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers